The use of interferon alfa-2a for life-threatening hemangiomas

C. J. MacArthur, Craig W Senders, J. Katz

Research output: Contribution to journalArticlepeer-review

50 Scopus citations


Hemangiomas are the most common benign neoplasm in the neonatal period. While most small hemangiomas involute spontaneously, up to 20% may grow to a massive size and never completely involute. Massive hemangiomas are also frequently associated with life-threatening complications, such as airway obstruction, platelet trapping (Kasabach-Merritt syndrome), and high-output heart failure. The use of interferon alfa-2a for the treatment of massive hemangiomas not responsive to traditional therapy has recently been reported. We present the successful use of interferon alfa-2a in a series of five patients with massive hemangiomas complicated by airway compromise, congestive heart failure, need for tracheotomy, Kasabach-Merritt syndrome, and failure to thrive, despite traditional therapy.

Original languageEnglish (US)
Pages (from-to)690-693
Number of pages4
JournalArchives of Otolaryngology - Head and Neck Surgery
Issue number6
StatePublished - 1995

ASJC Scopus subject areas

  • Otorhinolaryngology


Dive into the research topics of 'The use of interferon alfa-2a for life-threatening hemangiomas'. Together they form a unique fingerprint.

Cite this